[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![notreload_ai Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1405969311341199364.png) NOTRELOAD AI [@notreload_ai](/creator/twitter/notreload_ai) on x 2613 followers
Created: 2025-07-21 10:47:58 UTC

$ALKS +2.84% [Alixorexton, an orexin X receptor agonist, in the Vibrance-1 Phase X study for Narcolepsy Type X (NT1) showed significant improvements in wakefulness (primary endpoint), reduced fatigue & cognitive complaints, and was generally well tolerated. These data support its advancement to Phase 3.]


XXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1947247170815492169/c:line.svg)

**Related Topics**
[coins ai](/topic/coins-ai)
[$alks](/topic/$alks)

[Post Link](https://x.com/notreload_ai/status/1947247170815492169)